Which company produces the original drug regorafenib?

Regorafenib is a multi-target small molecule oral drug mainly used to treat a variety of advanced tumors, including hepatocellular carcinoma (HCC), colorectal cancer (CRC) and gastrointestinal stromal tumor (GIST). The original drug of regorafenib is produced by Bayer AG. Bayer is a leading global pharmaceutical and life sciences company headquartered in Germany. The company is committed to providing innovative drugs to the world and has a strong research and development background in oncology, cardiovascular diseases, gynecological diseases and other fields.

The development process of regorafenib originated from Bayer's in-depth research on anti-cancer targeted therapy. During the growth of tumor cells, specific signaling pathways are activated to promote the proliferation and spread of tumor cells. Regorafenib effectively controls tumor growth by inhibiting multiple targets in these signaling pathways, especially for multi-target malignant tumors. The pharmacological mechanism of regorafenib enables it to block the blood supply of tumor cells and reduce tumor angiogenesis, thereby achieving anti-tumor effects.

Sinceregorafenib was approved in 2011, it has been used for clinical treatment in many countries and regions. The multi-target effect of regorafenib not only enhances its anti-cancer broadness, but also makes it one of the options for the treatment of various advanced cancers. As an innovative drug from Bayer, the successful launch of regorafenib provides new treatment hope for many patients with advanced cancer.

In general, regorafenib, as a multi-target targeted therapy, has shown significant efficacy in the treatment of advanced tumors, especially colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma. It effectively reduces tumor angiogenesis and tumor cell proliferation by inhibiting multiple signaling pathways. However, due to the diversity of its side effects, patients need to strictly control the dosage of the drug under the guidance of a doctor and conduct regular health monitoring when using regorafenib.

Reference materials:https://www.stivarga-us.com/